ArticleVirchows Archiv : an international journal of pathology2025
Small papillary renal neoplasm with reverse polarity (≤ 15 mm) may challenge the current diagnostic criteria of papillary adenoma.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Case Report: Clinicopathological features of papillary renal neoplasm with reverse polarity: a report of four patients and literature review.Frontiers in oncology · 2026Article
- Recent developments in eosinophilic renal neoplasms: what's new, true and important?Histopathology · 2026Review
- Bilateral synchronous papillary renal neoplasm with reverse polarity and renal cell carcinoma with fibromyomatous stroma: a case report and review of the literature.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary renal neoplasm with reverse polarity (PRNRP), currently categorized as a papillary renal cell carcinoma (RCC) variant in the 5th edition of the WHO Classification, has shown increasing evidence of clinicopathological and molecular distinctions from conventional papillary RCC. Therefore, PRNRP should be separated from papillary RCC. Our analysis of 35 PRNRP cases with a mean tumor size of 15.0 mm demonstrated clinicopathological features consistent with prior reports. Uniform histological findings showed tumors with abundant eosinophilic cytoplasm and apically oriented low-grade nuclei, complemented by a consistent immunohistochemical profile of keratin 7 positivity and GATA3 expression. AMACR and vimentin expression were frequently negative. Fluorescence in situ hybridization detected abnormalities in chromosomes 7/17/Y in 4 cases. KRAS mutations were identified in 23 cases. Novel observations included that cystic architecture was more frequently observed in tumors exceeding 15 mm compared to their smaller counterparts (≤ 15 mm). Fifteen ≤ 15 mm PRNRP cases demonstrated an absence of fibrous capsule, meeting diagnostic criteria for papillary adenoma. However, comparative analysis of 45 papillary adenoma cases revealed distinct clinicopathological differences from PRNRP. These findings reinforce current proposals for distinguishing PRNRP from conventional papillary RCC. Furthermore, our data highlight a diagnostic conundrum regarding small (≤ 15 mm) PRNRP cases lacking fibrous capsules, which challenge current diagnostic boundaries between PRNRP and papillary adenoma. Future classification should address both the separation from papillary RCC and the need to refine the diagnostic criteria of papillary adenoma.
Indexed as
Identifiers
40448848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.